TB-500 and Thymosin Beta-4: What the Research Shows
Related Product
TB-500
Background
TB-500 is a synthetic peptide fragment corresponding to the active region of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid protein found in virtually all nucleated cells. Tβ4 was first isolated from thymic tissue in the 1960s and has been studied extensively for its role in actin sequestration and cytoskeletal organisation.
Actin Binding and Cellular Migration
The primary known function of Thymosin Beta-4 is binding to G-actin (monomeric actin), thereby regulating the pool of actin available for polymerisation. This has downstream effects on cell motility, morphology, and wound healing processes in cellular models.
Research has shown that Tβ4 promotes the migration of keratinocytes, endothelial cells, and cardiac cells in various in vitro models. The TB-500 fragment retains the actin-binding domain responsible for these observed effects.
Cardiovascular Research
A notable area of TB-500/Tβ4 research involves cardiac tissue. Studies in rodent models of myocardial infarction have examined whether Tβ4 administration affects cardiac progenitor cell activation and angiogenesis. These findings have generated interest in the compound as a research tool for cardiovascular biology.
Combination with BPC-157
Researchers frequently study TB-500 alongside BPC-157 due to their complementary proposed mechanisms — BPC-157 acting primarily through NO and growth factor pathways, while TB-500 acts through actin regulation. Several published animal studies have examined both compounds in the same model systems.
TB-500 is a research compound only. It has not been approved for therapeutic use in humans by any regulatory authority.
Research Disclaimer: This article is provided for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. All products are intended strictly for laboratory research and are not approved for human consumption.